StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research report report published on Thursday. The brokerage issued a sell rating on the stock.

InspireMD Stock Down 0.5 %

NYSE:NSPR opened at $2.00 on Thursday. InspireMD has a 52 week low of $1.29 and a 52 week high of $3.85. The company has a fifty day simple moving average of $2.30 and a two-hundred day simple moving average of $2.62. The company has a market cap of $46.80 million, a price-to-earnings ratio of -1.85 and a beta of 0.92.

InspireMD (NYSE:NSPR) last released its earnings results on Wednesday, March 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. The firm had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.65 million. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. During the same period in the previous year, the firm posted ($0.60) EPS. On average, analysts expect that InspireMD will post -0.61 EPS for the current year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. McKinley Carter Wealth Services Inc. bought a new stake in InspireMD, Inc. (NYSE:NSPR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $28,000. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.